stockrowSplash Beverage Group, Inc.
EDVA Healthcare Biotechnology
Splash Beverage Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $73,100.00, down 98.2% from fiscal 2024.
- Revenue
- −99.6%
- EPS
- +95.6%
- Free cash flow
- −95.7%
- Total debt
- −100.0%
Quarter to June 2026, against a year earlier
Follow EDVA
Alert me
Splash Beverage Group, Inc. (EDVA) EV/Sales
As of 6 November 2026, Splash Beverage Group, Inc. (EDVA) trades at a EV/Sales of 0.8×. Over the past ten years it has ranged from 0.4× (February 2026) to 1,244× (August 2019); the current reading is higher than 5% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.9× | (66.51%) |
| FY2024 | 2.6× | 113.53% |
| FY2023 | 1.2× | (26.77%) |
| FY2022 | 1.7× | (37.98%) |
| FY2021 | 2.7× | (90.78%) |
| FY2020 | 29.0× | (91.35%) |
| FY2019 | 335× | 2,416.86% |
| FY2018 | 13.3× | 0.00% |
| FY2017 | 13.3× | 0.00% |
| FY2016 | 13.3× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 2.2× | 154.23% |
| Dec 2025 | 0.9× | (52.13%) |
| Mar 2025 | 1.8× | (30.04%) |
| Dec 2024 | 2.6× | 13.98% |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SILO Silo Pharma, Inc. compare | −52.3× |
| BRTX Biorestorative Therapies, Inc. compare | −5.8× |
| GNPX GENPREX compare | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| ENLV Enlivex Ltd. compare | n/m |
| SLXN Silexion Therapeutics Corp compare | n/m |
| EDVA Splash Beverage Group, Inc. | 0.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)